WallStSmart

Boston Scientific Corp (BSX)vsNovocure Ltd (NVCR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 2963% more annual revenue ($20.07B vs $655.35M). BSX leads profitability with a 14.4% profit margin vs -20.8%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

NVCR

Avoid

30

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 4.8
Piotroski: 4/9Altman Z: -0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for NVCR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

NVCR0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

NVCR4 concerns · Avg: 2.3/10
Market CapQuality
$1.29B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-38.9%2/10

ROE of -38.9% — below average capital efficiency

EPS GrowthGrowth
-6.0%2/10

Earnings declined 6.0%

Free Cash FlowQuality
$-22.90M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : NVCR

NVCR has a balanced fundamental profile.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : NVCR

The primary concerns for NVCR are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

BSX profiles as a growth stock while NVCR is a turnaround play — different risk/reward profiles.

NVCR carries more volatility with a beta of 0.74 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 30/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Novocure Ltd

HEALTHCARE · MEDICAL DEVICES · USA

NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.

Want to dig deeper into these stocks?